Search
Research
Invasive fungal disease in children with solid tumors: An Australian multicenter 10-year reviewInvasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups are poorly defined. Retrospective national multicenter cohort data (2004-2013) were analyzed to document prevalence, clinical characteristics, and microbiology of IFD.
Research
Impact of Parent-Reported Antibiotic Allergies on Pediatric Antimicrobial Stewardship ProgramsAntimicrobial stewardship (AMS) is crucial for optimizing antimicrobial use and restraining emergence of antimicrobial resistance. The overall increase in reported antibiotic allergies in children can pose a significant barrier to AMS, but its impact on clinical AMS care in children has not been addressed.
Research
The mark of success: The role of vaccine-induced skin scar formation for BCG and smallpox vaccine-associated clinical benefitsSkin scar formation following Bacille Calmette-Guérin (BCG) or smallpox (Vaccinia) vaccination is an established marker of successful vaccination and 'vaccine take'. Potent pathogen-specific (tuberculosis; smallpox) and pathogen-agnostic (protection from diseases unrelated to the intentionally targeted pathogen) effects of BCG and smallpox vaccines hold significant translational potential.
News & Events
Shot in the arm for Strep A vaccine bidThe Leducq Foundation has bolstered an Australian-led bid to develop a Strep A vaccine, committing USD4.3 million to fund critical scientific work.
Research
COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statementThe Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.
News & Events
NHMRC funding awarded to support child health researchThe Kids Research Institute Australia researchers have been awarded more than $10 million in research funding from the National Health and Medical Research Council (NHMRC).
News & Events
Sharing the power of data at TEDx PerthDr Hannah Moore was one of WA’s brightest minds chosen to speak at TEDX Perth in November last year, presenting her insights into the power of data in fighting infectious diseases to a sold-out crowd at the Perth Concert Hall.
News & Events
First week of school visits mark official launch of the SToP TrialThe The Kids Skin Health team has a busy six weeks ahead - visiting nine communities throughout the Kimberley region of WA as part of the first school surveillance activities for the SToP Trial.
News & Events
Premature babies at greater risk of childhood infectionNew research has found children who are born even slightly premature or underweight are more likely to be hospitalised with an infection during their childhood
News & Events
Trans Tasman action to fast track rheumatic fever vaccinePrime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.